{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:20:59Z","timestamp":1789129259206,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41380-025-03341-1","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T19:44:29Z","timestamp":1763149469000},"page":"1909-1922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-249X","authenticated-orcid":false,"given":"N\u00faria","family":"Nadal-Gratac\u00f3s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2542-972X","authenticated-orcid":false,"given":"Pol","family":"Puigseslloses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5487-6505","authenticated-orcid":false,"given":"Nicola","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9077-4055","authenticated-orcid":false,"given":"Eline","family":"Pottie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Riera-Colomer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lardeux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0076-4946","authenticated-orcid":false,"given":"Nathalie","family":"Thiriet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselott","family":"K\u00e4llsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"P\u00e9rez-Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ketsela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Margall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Berzosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-4501","authenticated-orcid":false,"given":"David","family":"Pubill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Ettcheto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-348X","authenticated-orcid":false,"given":"Christophe","family":"Stove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0664-5964","authenticated-orcid":false,"given":"Marcello","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-7444","authenticated-orcid":false,"given":"Harald H.","family":"Sitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5078-366X","authenticated-orcid":false,"given":"Elena","family":"Escubedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-7398","authenticated-orcid":false,"given":"Raul","family":"L\u00f3pez-Arnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"3341_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264\u2013355.","journal-title":"Pharmacol Rev"},{"key":"3341_CR2","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1523\/JNEUROSCI.1121-22.2022","volume":"42","author":"SF Grieco","year":"2022","unstructured":"Grieco SF, Castr\u00e9n E, Knudsen GM, Kwan AC, Olson DE, Zuo Y, et al. Psychedelics and neural plasticity: therapeutic implications. J Neurosci. 2022;42:8439\u201349.","journal-title":"J Neurosci"},{"key":"3341_CR3","first-page":"464","volume":"9","author":"MA Geyer","year":"2024","unstructured":"Geyer MA. A brief historical overview of psychedelic research. Biol Psychiatry: Cognit Neurosci Neuroimaging. 2024;9:464\u201371.","journal-title":"Biol Psychiatry: Cognit Neurosci Neuroimaging"},{"key":"3341_CR4","unstructured":"World Health Organization (WHO). Depression. https:\/\/www.who.int\/health-topics\/depression#tab=tab_1. Accessed date 25-02-2025."},{"key":"3341_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2147\/NDT.S198774","volume":"16","author":"D Voineskos","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatric Dis Treat. 2020;16:221\u201334.","journal-title":"Neuropsychiatric Dis Treat"},{"key":"3341_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/PPA.S29716","volume":"6","author":"KS Al-Harbi","year":"2012","unstructured":"Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369\u201388.","journal-title":"Patient Prefer Adherence"},{"key":"3341_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","volume":"235","author":"RL Carhart-Harris","year":"2018","unstructured":"Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235:399\u2013408.","journal-title":"Psychopharmacology"},{"key":"3341_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychological Med. 2019;49:655\u201363.","journal-title":"Psychological Med"},{"key":"3341_CR9","doi-asserted-by":"publisher","first-page":"117906951880050","DOI":"10.1177\/1179069518800508","volume":"12","author":"DE Olson","year":"2018","unstructured":"Olson DE. Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 2018;12:1179069518800508.","journal-title":"J Exp Neurosci"},{"key":"3341_CR10","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:4889\u2013499.","journal-title":"Cell Rep"},{"key":"3341_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41386-021-01101-7","volume":"47","author":"DA Pizzagalli","year":"2022","unstructured":"Pizzagalli DA, Roberts AC. Prefrontal cortex and depression. Neuropsychopharmacology. 2022;47:225\u201346.","journal-title":"Neuropsychopharmacology"},{"key":"3341_CR12","doi-asserted-by":"publisher","first-page":"8056370","DOI":"10.1155\/2016\/8056370","volume":"2016","author":"H Qiao","year":"2016","unstructured":"Qiao H, Li MX, Xu C, Chen HBin, An SC, Ma XM. Dendritic spines in depression: what we learned from animal models. Neural Plasticity. 2016;2016:8056370.","journal-title":"Neural Plasticity"},{"key":"3341_CR13","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.biopsych.2010.12.015","volume":"69","author":"N Li","year":"2011","unstructured":"Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69:754\u201361.","journal-title":"Biol Psychiatry"},{"key":"3341_CR14","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"LX Shao","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u201344-e4.","journal-title":"Neuron"},{"key":"3341_CR15","unstructured":"Shulgin AT, Shulgin Ann. Pihkal : a chemical love story. Transform Press 1991."},{"key":"3341_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109836","volume":"37","author":"M de la Fuente Revenga","year":"2021","unstructured":"de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37:109836.","journal-title":"Cell Rep"},{"key":"3341_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2024.137845","volume":"834","author":"BG Ferri","year":"2024","unstructured":"Ferri BG, de Novais CO, Rojas VCT, Estevam ES, Dos Santos GJM, Cardoso RR, et al. Psychedelic 25H-NBOMe attenuates post-sepsis depression in rats. Neurosci Lett. 2024;834:137845.","journal-title":"Neurosci Lett"},{"key":"3341_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175926","volume":"955","author":"BG Ferri","year":"2023","unstructured":"Ferri BG, de Novais CO, Bonani RS, de Barros WA, de F\u00e1tima \u00c2, Vilela FC, et al. Psychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats. Eur J Pharmacol. 2023;955:175926.","journal-title":"Eur J Pharmacol"},{"key":"3341_CR19","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3390\/brainsci12111490","volume":"12","author":"C Jo","year":"2022","unstructured":"Jo C, Joo H, Youn D-H, Kim JM, Hong Y-K, Lim NY, et al. Rewarding and reinforcing effects of 25H-NBOMe in Rodents. Brain Sci. 2022;12:1490.","journal-title":"Brain Sci"},{"key":"3341_CR20","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1021\/acschemneuro.3c00196","volume":"14","author":"JG Lee","year":"2023","unstructured":"Lee JG, Hur KH, Hwang SBin, Lee S, Lee SY, Jang CG. Designer drug, 25D-NBOMe, has reinforcing and rewarding effects through change of a dopaminergic neurochemical system. ACS Chem Neurosci. 2023;14:2658\u201366.","journal-title":"ACS Chem Neurosci"},{"key":"3341_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.brainresbull.2019.07.002","volume":"152","author":"JY Seo","year":"2019","unstructured":"Seo JY, Hur KH, Ko YH, Kim K, Lee BR, Kim YJ, et al. A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Res Bull. 2019;152:19\u201326.","journal-title":"Brain Res Bull"},{"key":"3341_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12850","volume":"25","author":"RJP Custodio","year":"2020","unstructured":"Custodio RJP, Sayson LV, Botanas CJ, Abiero A, You KY, Kim M, et al. 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: evidence of abuse potential. Addiction Biol. 2020;25:e12850.","journal-title":"Addiction Biol"},{"key":"3341_CR23","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1113\/EP088870","volume":"105","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. Exp Physiol. 2020;105:1459\u201366.","journal-title":"Exp Physiol"},{"key":"3341_CR24","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.3389\/fphar.2021.749429","volume":"12","author":"N Nadal-Gratac\u00f3s","year":"2021","unstructured":"Nadal-Gratac\u00f3s N, Alberto-Silva AS, Rodr\u00edguez-Soler M, Urquizu E, Espinosa-Velasco M, J\u00e4ntsch K, et al. Structure\u2013activity relationship of novel second-generation synthetic cathinones: mechanism of action, locomotion, reward, and immediate-early genes. Front Pharmacol. 2021;12:2766.","journal-title":"Front Pharmacol"},{"key":"3341_CR25","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/jnc.16149","volume":"168","author":"AS Alberto-Silva","year":"2024","unstructured":"Alberto-Silva AS, Hemmer S, Bock HA, Alves da Silva L, Scott KR, Kastner N, et al. Bioisosteric analogs of MDMA: improving the pharmacological profile? J Neurochem. 2024;168:2022\u201342.","journal-title":"J Neurochem"},{"key":"3341_CR26","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41380-024-02506-8","volume":"29","author":"P Puigseslloses","year":"2024","unstructured":"Puigseslloses P, Nadal-Gratac\u00f3s N, Ketsela G, Weiss N, Berzosa X, Estrada-Tejedor R, et al. Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties. Mol Psychiatry. 2024;29:2346\u201358.","journal-title":"Mol Psychiatry"},{"key":"3341_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114251","volume":"182","author":"E Pottie","year":"2020","unstructured":"Pottie E, Dedecker P, Stove CP. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of \u03b2-arrestin 2 and miniG\u03b1q bioassays. Biochemical Pharmacol. 2020;182:114251.","journal-title":"Biochemical Pharmacol"},{"key":"3341_CR28","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1021\/acschemneuro.3c00267","volume":"14","author":"E Pottie","year":"2023","unstructured":"Pottie E, Poulie CBM, Simon IA, Harps\u00f8e K, D\u2019Andrea L, Komarov IV, et al. Structure-activity assessment and in-depth analysis of biased agonism in a set of phenylalkylamine 5-HT2A receptor agonists. ACS Chem Neurosci. 2023;14:2727\u201342.","journal-title":"ACS Chem Neurosci"},{"key":"3341_CR29","doi-asserted-by":"publisher","first-page":"12031","DOI":"10.1021\/acs.jmedchem.2c00702","volume":"65","author":"CBM Poulie","year":"2022","unstructured":"Poulie CBM, Pottie E, Simon IA, Harps\u00f8e K, D\u2019Andrea L, Komarov IV, et al. Discovery of \u03b2-arrestin-biased 25CN-NBOH-derived 5-HT2AReceptor agonists. J Medicinal Chem. 2022;65:12031\u201343.","journal-title":"J Medicinal Chem"},{"key":"3341_CR30","doi-asserted-by":"publisher","first-page":"15444","DOI":"10.1021\/acs.analchem.9b03104","volume":"91","author":"E Pottie","year":"2019","unstructured":"Pottie E, Cannaert A, Van Uytfanghe K, Stove CP. Setup of a Serotonin 2A Receptor (5-HT2AR) bioassay: demonstration of its applicability to functionally characterize hallucinogenic new psychoactive substances and an explanation why 5-ht2ar bioassays are not suited for universal activity-based screening. Anal Chem. 2019;91:15444\u201352.","journal-title":"Anal Chem"},{"key":"3341_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110425","volume":"272","author":"N Nadal-Gratac\u00f3s","year":"2025","unstructured":"Nadal-Gratac\u00f3s N, Mata S, Puigseslloses P, De Macedo M, Lardeux V, Pain S, et al. Unveiling the potential abuse liability of \u03b1-D2PV: a novel \u03b1-carbon phenyl-substituted synthetic cathinone. Neuropharmacology. 2025;272:110425.","journal-title":"Neuropharmacology"},{"key":"3341_CR32","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s00204-020-02740-3","volume":"94","author":"K-H Hur","year":"2020","unstructured":"Hur K-H, Kim S-E, Lee B-R, Ko Y-H, Seo J-Y, Kim S-K, et al. 25C-NBF, a new psychoactive substance, has addictive and neurotoxic potential in rodents. Arch Toxicol. 2020;94:2505\u201316.","journal-title":"Arch Toxicol"},{"key":"3341_CR33","first-page":"287","volume":"6","author":"J Kehr","year":"2006","unstructured":"Kehr J, Yoshitake T. Monitoring brain chemical signals by microdialysis. Encycl Sens. 2006;6:287\u2013312.","journal-title":"Encycl Sens"},{"key":"3341_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1021\/ac202794q","volume":"84","author":"P Song","year":"2012","unstructured":"Song P, Mabrouk OS, Hershey ND, Kennedy RT. In vivo neurochemical monitoring using benzoyl chloride derivatization and liquid chromatography-mass spectrometry. Anal Chem. 2012;84:412\u20139.","journal-title":"Anal Chem"},{"key":"3341_CR35","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1021\/acs.jmedchem.9b01404","volume":"63","author":"LE Dunlap","year":"2020","unstructured":"Dunlap LE, Azinfar A, Ly C, Cameron LP, Viswanathan J, Tombari RJ, et al. Identification of Psychoplastogenic N, N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity Relationship Studies. J Medicinal Chem. 2020;63:1142\u201355.","journal-title":"J Medicinal Chem"},{"key":"3341_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature25509","volume":"554","author":"Y Yang","year":"2018","unstructured":"Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. 2018;554:317\u201322.","journal-title":"Nature"},{"key":"3341_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bcp.2019.02.004","volume":"163","author":"L Duart-Castells","year":"2019","unstructured":"Duart-Castells L, L\u00f3pez-Arnau R, Vizca\u00edno S, Camarasa J, Pubill D, Escubedo E. 7,8-Dihydroxyflavone blocks the development of behavioral sensitization to MDPV, but not to cocaine: differential role of the BDNF-TrkB pathway. Biochemical Pharmacol. 2019;163:84\u201393.","journal-title":"Biochemical Pharmacol"},{"key":"3341_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13578-023-01000-y","volume":"13","author":"T Espinosa-Jim\u00e9nez","year":"2023","unstructured":"Espinosa-Jim\u00e9nez T, Cano A, S\u00e1nchez-L\u00f3pez E, Olloquequi J, Folch J, Bull\u00f3 M, et al. A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of alzheimer\u2019s disease exacerbated with high fat diet. Cell Biosci. 2023;13:52.","journal-title":"Cell Biosci"},{"key":"3341_CR39","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1007\/s00213-018-5151-x","volume":"236","author":"AM Casaril","year":"2019","unstructured":"Casaril AM, Domingues M, Bampi SR, de Andrade Louren\u00e7o D, Padilha NB, Lenard\u00e3o EJ, et al. The selenium-containing compound 3-((4-chlorophenyl)selanyl)-1-methyl-1H-indole reverses depressive-like behavior induced by acute restraint stress in mice: modulation of oxido-nitrosative stress and inflammatory pathway. Psychopharmacology. 2019;236:2867\u201380.","journal-title":"Psychopharmacology"},{"key":"3341_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2022.114207","volume":"438","author":"M G\u0142uch-Lutwin","year":"2023","unstructured":"G\u0142uch-Lutwin M, Sa\u0142aciak K, Pytka K, Gawalska A, Jamrozik M, \u015aniecikowska J, et al. The 5-HT1A receptor biased agonist, NLX-204, shows rapid-acting antidepressant-like properties and neurochemical changes in two mouse models of depression. Behavioural Brain Res. 2023;438:114207.","journal-title":"Behavioural Brain Res"},{"key":"3341_CR41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci USA. 2021;118:e2022489118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3341_CR42","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"ChengY-C Prusoff","year":"1973","unstructured":"Prusoff ChengY-C. WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacol. 1973;22:3099\u2013108.","journal-title":"Biochemical Pharmacol"},{"key":"3341_CR43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00210-008-0260-4","volume":"377","author":"FJ Ehlert","year":"2008","unstructured":"Ehlert FJ. On the analysis of ligand-directed signaling at G protein-coupled receptors. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. 2008;377:549\u201377.","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"key":"3341_CR44","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1124\/mol.111.072801","volume":"80","author":"S Rajagopal","year":"2011","unstructured":"Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, DeWire SM, et al. Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol. 2011;80:367\u201377.","journal-title":"Mol Pharmacol"},{"key":"3341_CR45","doi-asserted-by":"publisher","first-page":"e0175642","DOI":"10.1371\/journal.pone.0175642","volume":"12","author":"R Nehmea","year":"2017","unstructured":"Nehmea R, Carpenter B, Singhal A, Strege A, Edwards PC, White CF, et al. Mini-G proteins: novel tools for studying GPCRs in their active conformation. PLoS ONE. 2017;12:e0175642.","journal-title":"PLoS ONE"},{"key":"3341_CR46","doi-asserted-by":"publisher","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","volume":"167","author":"AL Halberstadt","year":"2020","unstructured":"Halberstadt AL, Chatha M, Klein AK, Wallach J, Brandt SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology. 2020;167:107933.","journal-title":"Neuropharmacology"},{"key":"3341_CR47","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1080\/14656566.2023.2281582","volume":"24","author":"M Kalfas","year":"2023","unstructured":"Kalfas M, Taylor RH, Tsapekos D, Young AH. Psychedelics for treatment resistant depression: are they game changers? Expert Opin Pharmacotherapy. 2023;24:2117\u201332.","journal-title":"Expert Opin Pharmacotherapy"},{"key":"3341_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neuropharm.2018.01.049","volume":"142","author":"DJ Heal","year":"2018","unstructured":"Heal DJ, Gosden J, Smith SL. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology. 2018;142:89\u2013115.","journal-title":"Neuropharmacology"},{"key":"3341_CR49","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1139\/jpn.0427","volume":"29","author":"P Celada","year":"2004","unstructured":"Celada P, Puig MV, Amarg\u00f3s-Bosch M, Adell A, Artigas F. The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. 2004;29:252\u201365.","journal-title":"J Psychiatry Neurosci"},{"key":"3341_CR50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","volume":"14","author":"LP Cameron","year":"2023","unstructured":"Cameron LP, Patel SD, Vargas MV, Barragan EV, Saeger HN, Warren HT, et al. 5-HT2ARs mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci. 2023;14:351\u20138.","journal-title":"ACS Chem Neurosci"},{"key":"3341_CR51","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","volume":"99","author":"A Rickli","year":"2015","unstructured":"Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology. 2015;99:546\u201353.","journal-title":"Neuropharmacology"},{"key":"3341_CR52","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","volume":"35","author":"RA Glennon","year":"1984","unstructured":"Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984;35:2505\u201311.","journal-title":"Life Sci"},{"key":"3341_CR53","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.neuropharm.2013.08.025","volume":"77","author":"AL Halberstadt","year":"2014","unstructured":"Halberstadt AL, Geyer MA. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology. 2014;77:200\u20137.","journal-title":"Neuropharmacology"},{"key":"3341_CR54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.neuropharm.2018.02.033","volume":"142","author":"JS Elmore","year":"2018","unstructured":"Elmore JS, Decker AM, Sulima A, Rice KC, Partilla JS, Blough BE, et al. Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology. 2018;142:240\u201350.","journal-title":"Neuropharmacology"},{"key":"3341_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.760671","volume":"12","author":"J Reckweg","year":"2021","unstructured":"Reckweg J, Mason NL, van Leeuwen C, Toennes SW, Terwey TH, Ramaekers JG. A Phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in healthy volunteers. Front Pharmacol. 2021;12:760671.","journal-title":"Front Pharmacol"},{"key":"3341_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1133414","volume":"14","author":"JT Reckweg","year":"2023","unstructured":"Reckweg JT, van Leeuwen CJ, Henquet C, van Amelsvoort T, Theunissen EL, Mason NL, et al. A phase 1\/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psychiatry. 2023;14:1133414.","journal-title":"Front Psychiatry"},{"key":"3341_CR57","doi-asserted-by":"publisher","first-page":"113612","DOI":"10.1016\/j.biopha.2022.113612","volume":"154","author":"I Erkizia-Santamar\u00eda","year":"2022","unstructured":"Erkizia-Santamar\u00eda I, Alles-Pascual R, Horrillo I, Meana JJ, Ortega JE. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomedicine Pharmacotherapy. 2022;154:113612.","journal-title":"Biomedicine Pharmacotherapy"},{"key":"3341_CR58","doi-asserted-by":"publisher","first-page":"14148","DOI":"10.3390\/ijms232214148","volume":"23","author":"O Shahar","year":"2022","unstructured":"Shahar O, Botvinnik A, Esh-Zuntz N, Brownstien M, Wolf R, Lotan A, et al. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: translational implications. Int J Mol Sci. 2022;23:14148.","journal-title":"Int J Mol Sci"},{"key":"3341_CR59","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","volume":"38","author":"EJ Kyzar","year":"2017","unstructured":"Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. Psychedelic drugs in biomedicine. Trends Pharmacol Sci. 2017;38:992\u20131005.","journal-title":"Trends Pharmacol Sci"},{"key":"3341_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/7854_2017_478","volume":"36","author":"JF L\u00f3pez-Gim\u00e9nez","year":"2018","unstructured":"L\u00f3pez-Gim\u00e9nez JF, Gonz\u00e1lez-Maeso J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45\u201373.","journal-title":"Curr Top Behav Neurosci"},{"key":"3341_CR61","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","volume":"182","author":"K Kim","year":"2020","unstructured":"Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, et al. Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell. 2020;182:1574\u20137.e19.","journal-title":"Cell"},{"key":"3341_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44016-1","volume":"14","author":"J Wallach","year":"2023","unstructured":"Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023;14:8221.","journal-title":"Nat Commun"},{"key":"3341_CR63","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1111\/bph.13981","volume":"174","author":"E Ayme-Dietrich","year":"2017","unstructured":"Ayme-Dietrich E, Lawson R, C\u00f4t\u00e9 F, de Tapia C, Da Silva S, Ebel C, et al. The role of 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors. Br J Pharmacology. 2017;174:4123\u201339.","journal-title":"Br J Pharmacology"},{"key":"3341_CR64","unstructured":"Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Psychedelic Drugs: Consid Clin Investigations Guidance Ind DRAFT GUIDANCE. 2023."},{"key":"3341_CR65","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1021\/acsptsci.2c00222","volume":"6","author":"GC Glatfelter","year":"2022","unstructured":"Glatfelter GC, Naeem M, Pham DNK, Golen JA, Chadeayne AR, Manke DR, et al. Receptor binding profiles for tryptamine psychedelics and effects of 4-propionoxy-N,N-dimethyltryptamine in Mice. ACS Pharmacology Transl Sci. 2022;6:567\u201377.","journal-title":"ACS Pharmacology Transl Sci"},{"key":"3341_CR66","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s12640-020-00297-8","volume":"39","author":"A Wojtas","year":"2021","unstructured":"Wojtas A, Herian M, Skawski M, Soboci\u0144ska M, Gonz\u00e1lez-Mar\u00edn A, Noworyta-Soko\u0142owska K, et al. Neurochemical and behavioral effects of a new hallucinogenic compound 25B-NBOMe in rats. Neurotox Res. 2021;39:305\u201326.","journal-title":"Neurotox Res"},{"key":"3341_CR67","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/FBP.0000000000000309","volume":"28","author":"MB Gatch","year":"2017","unstructured":"Gatch MB, Dolan SB, Forster MJ. Locomotor and discriminative stimulus effects of four novel hallucinogens in rodents. Behavioural Pharmacol. 2017;28:375\u201385.","journal-title":"Behavioural Pharmacol"},{"key":"3341_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.875722","volume":"13","author":"M Tirri","year":"2022","unstructured":"Tirri M, Bilel S, Arf\u00e8 R, Corli G, Marchetti B, Bernardi T, et al. Effect of -NBOMe compounds on sensorimotor, motor, and prepulse inhibition responses in mice in comparison with the 2C analogs and lysergic acid diethylamide: from preclinical evidence to forensic implication in driving under the influence of drugs. Front Psychiatry. 2022;13:875722.","journal-title":"Front Psychiatry"},{"key":"3341_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96736-3","volume":"11","author":"RM Rodriguiz","year":"2021","unstructured":"Rodriguiz RM, Nadkarni V, Means CR, Pogorelov VM, Chiu YT, Roth BL, et al. LSD-stimulated behaviors in mice require \u03b2-arrestin 2 but not \u03b2-arrestin 1. Sci Rep. 2021;11:17690.","journal-title":"Sci Rep"},{"key":"3341_CR70","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/sj.npp.1301324","volume":"32","author":"FX Vollenweider","year":"2007","unstructured":"Vollenweider FX, Csomor PA, Knappe B, Geyer MA, Quednow BB. The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. neuropsychopharmacology: official publication of the american college of neuropsychopharmacology. Neuropsychopharmacology. 2007;32:1876\u201387.","journal-title":"Neuropsychopharmacology"},{"key":"3341_CR71","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","volume":"36","author":"HH Sitte","year":"2015","unstructured":"Sitte HH, Freissmuth M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015;36:41\u201350.","journal-title":"Trends Pharmacol Sci"},{"key":"3341_CR72","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.neuint.2019.02.007","volume":"125","author":"SY Jeon","year":"2019","unstructured":"Jeon SY, Kim Y-H, Kim SJ, Suh SK, Cha HJ. Abuse potential of 2-(4-iodo-2, 5-dimethoxyphenyl)N-(2-methoxybenzyl)ethanamine (25INBOMe); in vivo and ex vivo approaches. Neurochemistry Int. 2019;125:74\u201381.","journal-title":"Neurochemistry Int"},{"key":"3341_CR73","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/00008877-200209000-00008","volume":"13","author":"ND Volkow","year":"2002","unstructured":"Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behavioural Pharmaco. 2002;13:355\u201366.","journal-title":"Behavioural Pharmaco"},{"key":"3341_CR74","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.neuropharm.2004.06.032","volume":"47","author":"G Di Chiara","year":"2004","unstructured":"Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47:227\u201341.","journal-title":"Neuropharmacology"},{"key":"3341_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2023.109713","volume":"240","author":"A Wojtas","year":"2023","unstructured":"Wojtas A, Herian M, Ma\u0107kowiak M, Solarz A, Wawrzczak-Bargiela A, Bysiek A, et al. Hallucinogenic activity, neurotransmitters release, anxiolytic and neurotoxic effects in Rat\u2019s brain following repeated administration of novel psychoactive compound 25B-NBOMe. Neuropharmacology. 2023;240:109713.","journal-title":"Neuropharmacology"},{"key":"3341_CR76","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3389\/fphar.2019.01406","volume":"10","author":"C Miliano","year":"2019","unstructured":"Miliano C, Marti M, Pintori N, Castelli MP, Tirri M, Arf\u00e8 R, et al. Neurochemical and behavioral profiling in male and female rats of the psychedelic agent 25I-NBOMe. Front Pharmacol. 2019;10:1406.","journal-title":"Front Pharmacol"},{"key":"3341_CR77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/7854_2016_18","volume":"32","author":"SS Negus","year":"2017","unstructured":"Negus SS, Banks ML. Decoding the structure of abuse potential for new psychoactive substances: structure-activity relationships for abuse-related effects of 4-substituted methcathinone analogs. Curr Top Behav Neurosci. 2017;32:119\u201331.","journal-title":"Curr Top Behav Neurosci"},{"key":"3341_CR78","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.2174\/156802606778522131","volume":"6","author":"M Bubar","year":"2006","unstructured":"Bubar M, Cunningham K. Serotonin 5-HT2A and 5-HT2C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Medicinal Chem. 2006;6:1971\u201385.","journal-title":"Curr Top Medicinal Chem"},{"key":"3341_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.767","volume":"9","author":"EJ Campbell","year":"2021","unstructured":"Campbell EJ, Bonomo Y, Pastor A, Collins L, Norman A, Galettis P, et al. The 5-HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: a pilot study in treatment-seeking individuals. Pharmacol Res Perspect. 2021;9:e00767.","journal-title":"Pharmacol Res Perspect"},{"key":"3341_CR80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48:104\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"3341_CR81","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589:474\u20139.","journal-title":"Nature"},{"key":"3341_CR82","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1126\/science.1222939","volume":"338","author":"RS Duman","year":"2012","unstructured":"Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68\u201372.","journal-title":"Science"},{"key":"3341_CR83","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41583-024-00876-0","volume":"26","author":"C Liao","year":"2024","unstructured":"Liao C, Dua AN, Wojtasiewicz C, Liston C, Kwan AC. Structural neural plasticity evoked by rapid-acting antidepressant interventions. Nat Rev Neurosci. 2024;26:101\u201314.","journal-title":"Nat Rev Neurosci"},{"key":"3341_CR84","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41596-018-0011-z","volume":"13","author":"M-Y Liu","year":"2018","unstructured":"Liu M-Y, Yin C-Y, Zhu L-J, Zhu X-H, Xu C, Luo C-X, et al. Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc. 2018;13:1686\u201398.","journal-title":"Nat Protoc"},{"key":"3341_CR85","doi-asserted-by":"crossref","unstructured":"Can A, Dao DT, Terrillion CE, Piantadosi SC, Bhat S, Gould TD. The tail suspension test. J Visualized Experiments. 2012;59:e3769.","DOI":"10.3791\/3769-v"},{"key":"3341_CR86","doi-asserted-by":"crossref","unstructured":"Noble RE. Depression in women. Metabolism: Clinical and Experimental. 2005;54:49\u201352.","DOI":"10.1016\/j.metabol.2005.01.014"},{"key":"3341_CR87","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neuropharm.2017.11.022","volume":"130","author":"AM Dossat","year":"2018","unstructured":"Dossat AM, Wright KN, Strong CE, Kabbaj M. Behavioral and biochemical sensitivity to low doses of ketamine: influence of estrous cycle in C57BL\/6 mice. Neuropharmacology. 2018;130:30\u201341.","journal-title":"Neuropharmacology"},{"key":"3341_CR88","unstructured":"Gaidica M Rat Brain Atlas. https:\/\/labs.gaidi.ca\/rat-brain-atlas\/. Accessed date 15-01-2025."}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03341-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03341-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03341-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T09:06:56Z","timestamp":1773824816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03341-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3341"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03341-1","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"8 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}